Cholesterol bloodstream The multicenter, double-blind, placebo-controlled HAUSER-RCT study assessed the efficacy and safety of evolocumab in 157 patients aged 10 to 17 years with HeFH. Positive ...

The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH. The Food and Drug Administration (FDA) has approved Repatha (evolocumab) injection as an adjunct to ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

PCSK9 Inhibitor Evolocumab Significantly Reduces Adverse Cardiovascular Events When Added to Statin Therapy With No Major Safety Concerns Data from the first successfully completed dedicated outcomes ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

Amgen announced new detailed data from two phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a ...

All patients in the extension program were treated with open label evolocumab resulting in no concurrent placebo arm during this period. Although not all patients participated in FOURIER-OLE, baseline ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...